#tradingfloorai | #DXRX |  #Revenuegrows #Revenuesgrew #Revenuegrowth #Aheadofplan | Diaceutics PLC, a technology and solutions provider to the pharma and biotech industry, released its trading update for the fiscal year ended December 31, 2024 (FY 2024). The company reported strong financial and operational performance, with revenue growth of 39% on a constant currency basis, totaling £32.2 million. Adjusted EBITDA is expected to be marginally ahead of analyst consensus estimates. The companys order book and Annual Recurring Revenue (ARR) provide good visibility for continued growth in 2025. Diaceutics secured multiple enterprise-wide engagements and increased its customer base, working with 18 of the top 20 global pharma companies. The companys strong balance sheet and successful product launches contribute to its positive outlook, expecting a return to profitability in 2025. The precision medicine market opportunity is significant and growing, and Diaceutics is well-positioned to capitalize on it. The company also announced a change in the Remuneration Committee Chair and provided a notice of its expected preliminary results release in early May 2025. Read More@: